Prescient Therapeutics Limited · ASX:PTX
Prescient Therapeutics — Investor Presentation (March 2025)
33 slides from Prescient Therapeutics's investor presentation, Mar 31, 2025
Slide 1: Prescient Therapeutics – Investor Briefing
Prescient Therapeutics – Investor Briefing MELBOURNE Australia, 31st March 2025: Prescient Therapeutics Limited (ASX: PTX), a clinical stage oncology company developing personalised therapies for cancer, will be holding an investor briefing on Monday, 31st March at 12pm (AEDT). CEO James McDonnell w
Slide 2: About Prescient: CellPryme-A and OmniCAR platforms
CellPryme-A: CellPryme-A is an adjuvant therapy designed to be administered to patients alongside cellular immunotherapy to help them overcome a suppressive tumour microenvironment. CellPryme-A significantly decreases suppressive regulatory T cells; increases expansion of CAR-T cells in vivo; increa
Slide 3: Disclaimer and Safe Harbor Statement
Disclaimer and Safe Harbor Statement Certain statements made in this document are forward-looking statements within the meaning of the safe harbor provisions of the United States Private Securities Litigation Reform Act of 1995. These forward-looking statements are not historical facts but rather ar
Slide 4: For personal use only
For personal use only ASX: PTX
Slide 5: Disclaimer and Safe Harbor
DISCLAIMER AND SAFE HARBOR For personal use only Certain statements made in this document are forward-looking statements within the meaning of the safe harbor provisions of the United States Private Securities Litigation Reform Act of 1995. These forward-looking statements are not historical facts b
Slide 6: Key Messages
3 Key Messages For personal use only A major inflection point with Phase 2 Initiation 1 PTX-100 • Phase 2a clinical trial has begun • Encouraging data in an area of unmet need • First in class with a wider application Lower risk exposure to cell therapy sector 2 • Improves 3rd party cell therapies •
Slide 7: PTX: Targeting Improved Oncology Patient Outcomes
PTX: Targeting Improved Oncology Patient Outcomes Through novel approaches to treat cancer including targeted and cell therapies For personal use only Led by an experienced team of drug developers and deal makers with a track record in blood cancers PTX-100 • Targeted therapy – one of the most advan
Slide 8: Experienced team
Experienced team For personal use only • Experienced team of drug developers and deal makers with track record in blood cancers Management Team Experienced gained in global companies Board of Directors 5
Slide 9: Investment Snapshot
Investment Snapshot For personal use only Share price performance over past 12 months ASX Ticker PTX Total Issued Capital 805 M shares Share Price1 A$0.048 Top 20 Own 18% Market Capitalisation1 $39M Near-term Liquidity2 $12.1M Enterprise Value $27M 1. As at 28 March 2025 2. Near-term Liquidity (Jan
Slide 10: Portfolio Overview
For personal use only Portfolio Overview 7
Slide 11: PTX-100 First in Class Targeted Therapy
PTX-100 First in Class Targeted Therapy For personal use only Inhibition of GGT-1 disrupts small GTPases including: the RAS family pathway • Mutations in RAS are estimated to be responsible for approximately 22% of all human cancers1 • PTX-100 targets and blocks an enzyme called GGTase-1, disrupting
Slide 12: CellPryme: enhancing cell therapies in two ways
CellPryme: enhancing cell therapies in two ways For personal use only MANUFACTURING ADJUVANT Synergy Effect Enhanced Effectiveness Seamless addition during manufacturing Safely administrated to patient Enhanced CAR-T phenotype Enhanced CAR-T therapy 9
Slide 13: OmniCAR: modular “plug & play” cells
OmniCAR: modular “plug & play” cells For personal use only Traditional “Plug & play” CAR-T products offers: • Permanent target • Increased flexibility • Modular/Adaptable • Single target • Multiantigen target • Multi-target • Fixed • Better control over cell function • Tuneable 10
Slide 14: First in class targeted therapy
IST IN CLASS TARGETED THERAPY Yale University es MOFFITT (i)
Slide 15: Cutaneous T-cell Lymphoma (CTCL) Overview
Cutaneous T-cell Lymphoma (CTCL) Overview For personal use only • A rare type of cancer of white blood cells (T cells), normally involved in immune function • These cancerous T cells travel to and live in the skin, where they grow and divide uncontrollably, attacking the skin • CTCLs include subtype
Slide 16: Cutaneous T-cell Lymphomas (CTCL): a serious unmet need
Cutaneous T-cell Lymphomas (CTCL) a serious unmet need For personal use only Professor Miles Prince “Unfortunately, T-Cell lymphomas (…) is universally incurable in patients that have not responded to initial therapy. So, we are in desperate need of a treatment that will allow patients to respond an
Slide 17: For personal use only
For personal use only 14
Slide 18: Before / After patient response
Before After For personal use only “We are seeing responses in our patients who weren’t responding to any other treatments” Professor H. Miles Prince Principal Investigator 15
Slide 19: PTX-100 Phase 1b responses: Strong response rates
PTX-100 Phase 1b responses: Strong response rates in evaluable patients For personal use only PTX-100 Benchmark1 Lymphir2,3 (Phase 1B) Response Rate 30% 36% 45% Clinical Benefit Rate 45% NA 64% Duration of 9-13 months CTCL Response 6.5 months (CTCL) 10.7 months 3-4 Months PTCL Serious Adverse Events
Slide 20: PTX-100: Favorable safety profile compared to peers
PTX-100: Favorable safety profile compared to peers Recommended CTCL drugs, as outlined in international cancer treatment guidelines, have For personal use only challenging safety profiles, with adverse events occurring in up to 70% of patients Adverse Events Associated with current Marketed Drugs*
Slide 21: Rationale of prioritising r/r CTCL for Ph2 trial
Rationale of prioritising r/r CTCL for Ph2 trial For personal use only CTCL PTCL • Higher confidence of PTX-100 in CTCL • Peripheral T Cell Lymphoma (PTCL) is more (more data; more responders) prevalent than CTCL, but even though PTCL is still an unmet need, it has more existing • Greater need for n
Slide 22: Progressing PTX-100 to Phase 2
Progressing PTX-100 to Phase 2 For personal use only Dose Confirmation r/r CTCL 500mg/m2 x 20 pts Randomization 2nd Line Enrolment Phase 2a Optimisation Phase 2b Efficacy DOC X40 X 75 pts patients (pts) 1000mg/m2 x 20 pts Up to 2 years Multicenter clinical trial • Phase 2a: N=40 pts with r/r CTCL (d
Slide 23: Aiming for shortened registrational pathway
Aiming for shortened registrational pathway For personal use only Regular drug development process Years & $$$ saved Potential for Registrational study Adapted from Capuano, A. et al; Front. In Pharmacol.; Feb 2019 20
Slide 24: Aiming for shortened registrational pathway
Aiming for shortened registrational pathway For personal use only Regular drug development process PTX-100 Benchmark1 (Phase 1B) Response Rate 30% 45% Clinical Benefit Rate 45% 64% Duration of 9-13 months CTCL Potential for 10.7 months Response 3-4 Months PTCL Registrational study Serious Adverse >3
Slide 25: Advantages of Orphan Drugs
Advantages of Orphan Drugs For personal use only Orphan 11.6% CAGR 7 7 years of guaranteed market exclusivity in US Non-orphan 7% CAGR (10 years in Europe) Higher prices Consistently higher sales growth than non-orphan drugs Sales are more resilient Total orphan sales to cycles to reach $US300B by 2
Slide 26: T-cell lymphomas (TCL): High unmet need = Large market opportunity
T-cell lymphomas (TCL): High unmet need = Large market opportunity For personal use only Total Addressable Market (TAM) CTCL US alone • 27,263 new cases / year in the 8 major • Incidence 3,000 patients /annum# markets • Almost all will relapse • Almost all will relapse • Combination therapy likely •
Slide 27: Key Milestones in the near future
Key Milestones in the near future: Implementation will drive value For personal use only Key Milestones Expected Timing (CY) First patient in and dosed with PTX-100 (FPID) April/May Potential FDA Fast Track designation Q2 First US site activated and recruiting Q2/3 First European site activated and
Slide 28: First in Class PTX-100 beyond TCL
First in Class PTX-100 beyond TCL For personal use only • First in class enzyme inhibitor disrupting the RAS super - family pathway, in particular, RHO, RAC and RAL • 22% of all cancers have RAS involvement Examples: • The RAS super family of genes consists of RAL, RAC, RHO-A/B, plus N-RAS and K-RAS
Slide 29: Summing up PTX-100: Driving a major inflection point
Summing up PTX-100: Driving a major inflection point For personal use only Results: Timelines: Phase 1b • Phase 2a is starting now • 64% Clinical Benefit • Multiple sites globally • 10.7 months Duration of Response • International experts involved • 4% ≥ Grade 3 SAE • Recruitment will drive timing •
Slide 30: Key Messages
3 Key Messages For personal use only A major inflection point with Phase 2 Initiation 1 PTX-100 • Phase 2a clinical trial has begun • Encouraging data in an area of unmet need • First in class with a wider application Lower risk exposure to cell therapy sector 2 • Improves 3rd party cell therapies •
Slide 31: For personal use only
For personal use only ASX: PTX
Slide 32: First in Class Targeted Therapy
First in Class Targeted Therapy For personal use only Inhibition of GGT-1 disrupts small GTPases including: the RAS family pathway • Mutations in RAS are estimated to be responsible for approximately 22% of all human cancers1 • PTX-100 targets and blocks an enzyme called GGTase-1, disrupting the RAS
Slide 33: PTX-100 Phase 1b responses: Strong response rates
PTX-100 Phase 1b responses: Strong response rates in evaluable patients For personal use only PTX-100 Benchmark1 Lymphir2,3 (Phase 1B) Response Rate 30% 36% 45% Clinical Benefit Rate 45% NA 64% Duration of 9-13 months CTCL Response 6.5 months (CTCL) 10.7 months 3-4 Months PTCL Serious Adverse Events
Prescient Therapeutics — Investor Presentation (March 2025) on 6ix